Over the next six years, the purchase and production of biosimilar drugs can expect to see high double-digit growth. Are you familiar with the trends driving growth in the hottest market in therapeutic development?
CDISC standards are now mandatory. Your organization can either treat them as another regulatory weight, or use them to mitigate risk, drive down costs, and increase efficiency.
Biorasi is not just a contract research organization. We are Clinical Research Optimized™, which means that we achieve the ideal balance of cost, time and risk management. Through innovative project management processes and technologies, dedication to our sponsors, and a culture of ownership, our team will deliver to you on time, on budget, results every time.
By some estimates, more than 90% of drug candidates never make it into consumer hands. That number shouldn’t come as a surprise to anyone who has spent time in pharma R&D, but thankfully most of those failed compounds fail early and relatively cheaply. What’s more...read more
For this week’s Biorasi Spotlight, meet Mark Vieder, RPH, MBA, Vice President of Drug Safety and Pharmacovigilance at Biorasi, LLC. 1. How did you get into clinical research? Being a health care professional (HCP) and having practiced for a number of years, I...read more
This week, the path to market for biosimilar developers cleared up just a bit. The Supreme Court made a final decision in the three-year lawsuit between Amgen and Sandoz that sets a precedent regarding the interpretation of some widely-contested language in the BPCI...read more